Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

NCT01455571 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HM781-36B

Sponsor

Hanmi Pharmaceutical Company Limited

Collaborators

[object Object]